Consensus estimates from Vara point to quarterly net sales of 13.25 billion euros, an uptick from the 12.43 billion euros recorded during the same period last year. Despite this growth, analysts anticipate business earnings per share of 2.81 euros, trailing the 2.91 euros reported in the third quarter of 2023. This financial performance follows a challenging stretch that saw Sanofi stock retreat 3.3% over the last three months.
In section Market Quotes
Sanofi Earnings Preview: Dealmaking Strategy Takes Center Stage
Investors are shifting focus toward Sanofi's acquisition appetite as the French pharmaceutical giant prepares to report third-quarter results this Friday. With the company’s share price sliding nearly 9% since January, market watchers are scrutinizing how leadership plans to bridge revenue gaps expected when its blockbuster drug Dupixent eventually loses patent protection.
Strategic direction remains the primary concern. CEO Belen Garijo has signaled a potential shift toward larger deals, following an expanded alliance with Regeneron Pharmaceuticals. Citi analysts suggest that investors will also look for clarity on the priorities of Paulo Fontoura, who stepped in as the new head of research and development in September. Beyond corporate strategy, the vaccine division faces significant headwinds. UBS analysts project a 13% decline in vaccine sales, citing a sluggish flu season and increased competitive pressure on the Beyfortus respiratory syncytial virus treatment. While Sanofi raised its 2026 growth guidance to 10% in July, market sentiment remains divided on whether the company will maintain that outlook or pursue another upgrade.
Comments (0)
No comments yet. Be the first!